← Eichor
Condition: Polycythemia Vera Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Polycythemia Vera

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ruxolitinib in Thrombocythemia and Polycythemia Vera
Phase 2 · 4 location(s) · Massachusetts General Hospital · NCT04644211Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Phase 1 · 7 location(s) · Novartis Pharmaceuticals · NCT07340138Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes
NA · 3 location(s) · University Hospital, Angers · NCT06361641A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Phase 3 · 30 location(s) · Novartis Pharmaceuticals · NCT073577273'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090Myeloproliferative Neoplastic Diseases Observatory From Brest
Phase N/A · 1 location(s) · University Hospital, Brest · NCT02897297Efficacy and Safety of Peginterferon in ET and PV.
NA · 1 location(s) · Zhenya Hong · NCT06734637Two Step Haplo With Radiation Conditioning
Phase 2 · 1 location(s) · Thomas Jefferson University · NCT05031897Therapeutic RSK1 Targeting in Myelofibrosis
Phase 1 · 1 location(s) · Washington University School of Medicine · NCT07379125Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly
Phase N/A · 1 location(s) · iOMEDICO AG · NCT06743035Blood Viscosity in Polycythemia Patients
Phase N/A · 1 location(s) · Hospices Civils de Lyon · NCT06421025Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Phase 1/Phase 2 · 28 location(s) · Disc Medicine, Inc · NCT05320198Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythem
Phase N/A · 6 location(s) · University Hospital, Angers · NCT05440838Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
Phase N/A · 37 location(s) · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS · NCT06506084A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Phase 1 · 21 location(s) · Ajax Therapeutics, Inc. · NCT06343805A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05714072Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Phase 2 · 1 location(s) · Chengdu Zenitar Biomedical Technology Co., Ltd · NCT07232290MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
Phase 3 · 47 location(s) · University of Birmingham · NCT04116502MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Phase 2 · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT06541249A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV
NA · 1 location(s) · Duan Minghui · NCT07445893Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera
Phase N/A · 26 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06516406INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Phase 3 · 6 location(s) · Ono Pharmaceutical Co., Ltd. · NCT07429266AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positiv
Phase 3 · 42 location(s) · University Hospital, Brest · NCT05198960Myeloproliferative Neoplasms (MPNs) Patient Registry
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT02760238Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05870475MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Phase 1 · 5 location(s) · Prelude Therapeutics · NCT07469891Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
Phase 3 · 6 location(s) · PharmaEssentia Japan K.K. · NCT04655092A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
Phase N/A · 3 location(s) · Bristol-Myers Squibb · NCT06073847Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Phase 2 · 33 location(s) · GlaxoSmithKline · NCT06517875
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.